secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2023-11-28T23:59:59+00:00
Accession:  0001645113-23-000050
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novocure announces $60M cost-cutting plan, cuts 200 jobs (13% of workforce)
---------------------------------------------------------------------------

- Reduction in residual operating expenses of ~$60M; includes 200 job cuts (13% of staff).
- One-time restructuring charge of ~$7M expected in Q4 2023.
- Pivots resources to launch readiness for metastatic NSCLC Tumor Treating Fields therapy.
- Plans two Phase 3 readouts in 2024: METIS (brain mets NSCLC) and PANOVA-3 (pancreatic).
- Prioritizes clinical trials TRIDENT, KEYNOTE D58, LUNAR-2 for greatest value.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511323000050/0001645113-23-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511323000050/nvcr-20231128.htm
  HTML page:      https://secwatch.observer/filing/0001645113-23-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer